Pfizer, Inc. (PFE) to Release Earnings on Monday
Pfizer, Inc. (NYSE:PFE) will post its quarterly earnings results before the market opens on Monday, October 30th. Analysts expect Pfizer to post earnings of $0.64 per share for the quarter. Pfizer has set its FY17 guidance at $2.54-2.60 EPS.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the company earned $0.64 earnings per share. On average, analysts expect Pfizer to post $2.56 EPS for the current fiscal year and $2.74 EPS for the next fiscal year.
Pfizer, Inc. (NYSE PFE) opened at 36.42 on Monday. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $36.60. The firm’s 50-day moving average is $35.56 and its 200-day moving average is $33.83. The firm has a market capitalization of $216.60 billion, a PE ratio of 26.64 and a beta of 1.00.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.51%. Pfizer’s dividend payout ratio is 94.12%.
Several brokerages recently commented on PFE. Jefferies Group LLC set a $38.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Monday, October 16th. Berenberg Bank reissued a “hold” rating and issued a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Barclays PLC set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $38.26.
In other news, CEO Ian C. Read sold 197,168 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares of the company’s stock, valued at $19,730,812. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 over the last three months. 0.06% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Raab & Moskowitz Asset Management LLC boosted its position in shares of Pfizer by 0.4% in the second quarter. Raab & Moskowitz Asset Management LLC now owns 150,284 shares of the biopharmaceutical company’s stock valued at $5,022,000 after acquiring an additional 670 shares during the period. Mountain Capital Investment Advisors Inc bought a new stake in shares of Pfizer in the second quarter valued at approximately $417,000. Auxier Asset Management boosted its position in shares of Pfizer by 0.9% in the second quarter. Auxier Asset Management now owns 85,668 shares of the biopharmaceutical company’s stock valued at $2,878,000 after acquiring an additional 800 shares during the period. First Fiduciary Investment Counsel Inc. boosted its position in shares of Pfizer by 1.2% in the second quarter. First Fiduciary Investment Counsel Inc. now owns 656,988 shares of the biopharmaceutical company’s stock valued at $22,068,000 after acquiring an additional 8,030 shares during the period. Finally, BW Gestao de Investimentos Ltda. bought a new stake in shares of Pfizer in the second quarter valued at approximately $2,015,000. 68.98% of the stock is owned by institutional investors.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.